Completed Access to Information Requests

About this information

Search the summaries of completed Access to Information (ATI) requests to find information about ATI requests made to the Government of Canada after January 2020. If you find a summary of interest, you can request a copy of the records at no cost using the form below each summary. Requests made through this form are considered informal requests and are not subject to the same requirements as requests under the Access to Information Act (ATIA).

If you don’t find what you are looking for you can request additional government records under an institution’s control by contacting the institution’s Access to Information and Privacy Coordinator or by submitting a formal access to information request.

*All information provided will incorporate the necessary exemptions and exclusions as per the Access to Information Act and the Privacy Act.

Download datasets of the summaries of completed access to information requests.

Current Search

Report Type

Organization

Disposition

Year

Month

Found 787 record(s)

Req # A-2024-000012

Adverse Drug Reactions (ADRs). Report numbers: 001067949, 001069982.

Organization: Health Canada

17 page(s)
April 2024

Req # A-2024-000017

Adverse Drug Reaction (ADR) for ACITRETIN. Report number: 1071472. ADRs for ANASTROZOLE. Report numbers: 983160, 990116. ADR for CIPROFLOX. Report number: 1032025. ADR for Clonidine. Report number: 981372. ADRs for EPLERENONE. Reports number: 1026516, 1043922. ADRs for HYDROXYCHLOROQUINE. Report numbers: 1024918, 1026702, 1037377.

Organization: Health Canada

70 page(s)
April 2024

Req # A-2024-000028

Adverse Drug Reactions (ADRs) for Rosuvastatin-40. Report numbers: 000657015, 000702528. ADRs for Rosuvastatin-10. Report numbers: 000675846, 000928844. ADRs for Rosuvastatin-5. Report numbers: 000698101, 000705573. ADRs for Rosuvastatin-20. Report numbers: 000709470, 000720165.

Organization: Health Canada

29 page(s)
April 2024

Req # A-2024-000032

Adverse Drug Reactions (ADRs) for IBUPROFEN. Report numbers: 001049833, 001051635, 001052031, 001052040, 001052619, 001050859, 001053224, 001055320, 001065019, 001065607.

Organization: Health Canada

76 page(s)
April 2024

Req # A-2024-000068

Adverse Drug Reaction (ADR) for YESCARTA. Report number: 001076510.

Organization: Health Canada

3 page(s)
April 2024

Req # N/A

No ATI request closed in April

Organization: Office of the Commissioner of Official Languages

0 page(s)
April 2024

Req # A-2015-000351

Application submissions and summary for new drug deferiprone licencing. Common Drug Review minutes kept of review process, Canadian Agency fo Drugs and Technologies in Health's (CADTH) interim and final report. Records from January 1, 2012 to January 4, 2016

Organization: Health Canada

692 page(s)
May 2023

Req # A-2017-001024

The reviewers reports, Module 1 and 2 regarding Information available fromNew Drug Submission (NDS) file - Submission Control No. 189720 AURO-CEFIXIME - DIN 02468689.

Organization: Health Canada

768 page(s)
May 2023

Req # A-2018-001007

All correspondence between the Health Products and Food Branch with the Canadian Patient Safety Institute related to plain language labeling and/or the self-care framework in 2018.

Organization: Health Canada

666 page(s)
May 2023

Req # A-2018-001858

Health Canada Reviewer Reports for Breo Ellipta Supplemental New Drug Submission Control Number 213290 Notice of Compliance (NOC) issued 2019-01-09.

Organization: Health Canada

85 page(s)
May 2023
Date modified: